Dual labeling of GBMs for RSK1 and CD68 showed that both CD68‐ (majority of cells) and CD68+ cells within the tumor express RSK1, which implies that RSK1 can indeed derive from both tumor and immune infiltrate cells. This evidence concerns the gene RPS6KA1 and neoplasm.